https://interactions.guidetherapeutiquevih.com/en/interaction-details?id=11310
No pharmaceutical opinion available for this interaction.
Elvitegravir / Cobicistat may inhibit the metabolism (CYP2D6) and decrease the conversion into morphine, active metabolite of Codeine.
–
–
Integrase inhibitor without cobicistat such as raltegravir, dolutegravir or bictegravir.
Possible decrease of clinical efficacy.
Monitor for clinical efficacy and adjust the dosage if necessary.
Depending on the clinical indication, acetaminophen, NSAIDs when possible, hydromorphone or morphine.
Signs and symptoms of opioid withdrawal : craving for opioids, irritability, myalgias, muscle spasms, flushing, abdominal pain, nausea, vomiting, diarrhea, restlessness, diaphoresis, lacrimation, rhinorrhea, mydriasis, yawning, piloerection (goose flesh), tachycardia, tremulousness.
–
–
–
–